Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes – GlobeNewswire

Posted on January 22, 2021 by Prof Baldwin

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

-Publication Further Supports Capricors Exosome Platform Advancement-

LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today the publication, in collaboration with researchers at Cedars-Sinai Medical Center, which demonstrates the utility of pathway-enhancing culture conditions and small molecule inhibitors to retain markers of cell therapy potency. The publication titled, Small molecule inhibitors and culture conditions enhance therapeutic cell and EV potency via activation of beta-catenin and suppression of THY1 was published in the international peer-reviewed journal, Nanomedicine: Nanotechnology, Biology and Medicine.

This data from this publication is of significant importance to Capricor because it demonstrates our approach to enhance potency of cells by targeting select signaling pathways. The ability to manipulate cells provides read through to our exosome product candidates which are being engineered to treat specific diseases. We have dedicated the last few years at Capricor to understanding the molecular composition of our exosomes products in order to identify microRNAs of interest for therapeutic development, said Dr. Linda Marbn, Ph.D., CEO of Capricor. This data was the foundation of our new platform, which has allowed us to expand our reach to engineering exosomes that contain RNAs for targeted therapeutic delivery. Further, this elucidation of the mechanisms that are driving potential potency of our cell therapy, CAP-1002 and the exosomes they secrete, correlate to some of the promising clinical data we have seen to date in Duchenne muscular dystrophy.

Key findings include:

Dr. Marbn continued, We know that the exosome is natures delivery system and can serve to carry a variety of biologic signals directly to the cell. Now, we have demonstrated that cells can make exosomes loaded with specific and powerful biologic signals. From these early studies, we have launched our platform which will include vaccines, treatment of monogenic diseases, as well as other targets. We plan to announce further pipeline expansion of our exosome-based product candidates by mid-2021.

The work at Cedars-Sinai Medical Center was supported by NIH R01124074; work by Capricor was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-16-1-0712. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.For more information, visitwww.capricor.comand follow the Company onFacebook,InstagramandTwitter.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricors exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:Caitlin Kasunich / Raquel ConaKCSA Strategic Communicationsckasunich@kcsa.com/ rcona@kcsa.com212.896.1241 / 212.896.1204

Investor Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com617.435.6602

Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com310.358.3200

Global Healthcare Nanotechnology (Nanomedicine) Market Top …

Posted on August 3, 2020 by Prof Baldwin

The MarketWatch News Department was not involved in the creation of this content.

Jul 29, 2020 (The Expresswire) --Global Healthcare Nanotechnology (Nanomedicine) Market Report 2020 (value and volume) by company, regions, product types, end industries, history data and estimate data. Also, Report contains a comprehensive analysis of the important segments like market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. This report focuses on the Healthcare Nanotechnology (Nanomedicine) in the Global market, especially in the United States, Europe, China, Japan, South Korea, North America, India.Healthcare Nanotechnology (Nanomedicine) Market report categorizes the market based on manufacturers, regions, type, and application. Healthcare Nanotechnology (Nanomedicine) Market reports offer a detailed assessment of the Healthcare Nanotechnology (Nanomedicine) including enabling technologies, current market situation, market assumptions, restraining factors.

The Global Healthcare Nanotechnology (Nanomedicine) market swot is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT - REQUEST SAMPLE

The global healthcare nanotechnology market was valued at USD 156.56 billion in 2017. This market is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2017. North America dominates the market, and is expected to maintain its position over the forecast period.

Rising applications in Oncology

Nanomedicine is a promising mode of cancer treatment and has several applications in oncology. Cancer has a major impact on United States and across the world. As per WHO, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million were the cancer-related deaths. Therefore the demand for nanomedicine in the market was in order to curb such high incidence rate and is expected to boost market. Researchers have been working on improvisation of techniques, to deliver chemotherapeutic agents precisely at the Nano level in tumorous tissues. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects and due their small size, nanoscale devices can readily interact with the biomolecules on both the surface and the inner cells and they have the potential to diagnose and treat cancer. Nanoparticles are majorly been used as nanocarriers, to deliver the cytotoxic drugs to the tumor cells and tissues. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the nanomedicines demand during the forecast period.

Huge costs of the medical devices

Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. Nanomedicines are no different; there are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Similarly, the average cost per dose of anticancer drug Abraxane, a paclitaxel nanoformulation, is USD 5,054. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine, relative to its traditional counterparts, is hindering the growth of the market.

US Healthcare Nanotechnology Market

The US-based pharmaceutical companies believe that nanomedicines is the next big thing, as it has been opening up newer and has more accurate options for the target drug delivery, and resulting in very few side effects. The Swiss Groups Kadcyla received the approval of the United States in February 2017. The product treats breast cancer with very less side-effects. In addition with the booming RandD, United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in healthcare. Owing to the large geriatric population, increasing need for diagnostics, growing need of augmented cancer therapies, government initiatives, and increasing awareness of nanomedicines, the US healthcare nanotechnology sector will witness substantial growth during the forecast period.

The key players in the market are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS Inc., JOHNSON and JOHNSON, MALLINCKRODT Plc, MERCK and COMPANY, Inc., NANOSPHERE, Inc., PFIZER, and CELGENE CORPORATION.

Get a Sample PDF of Report @https://www.360marketupdates.com/enquiry/request-sample/12884242

The global Healthcare Nanotechnology (Nanomedicine) market covers the vision of participant analysis by product types, market share, applications, sales, and revenue.

Healthcare Nanotechnology (Nanomedicine) Market Report covers the Top Key-players in 2020:-

Highlighted points of Healthcare Nanotechnology (Nanomedicine) Market Size:

Inquire more and share questions if any before the purchase on this report@https://www.360marketupdates.com/enquiry/pre-order-enquiry/12884242

This Healthcare Nanotechnology (Nanomedicine) Market Research/analysis Report Contains Answers to your following Questions

Key Developments in the Healthcare Nanotechnology (Nanomedicine) Market:

Reasons to Purchase this Report

Purchase this report (Price 4250 USD for a single-user license)@https://www.360marketupdates.com/purchase/12884242

Finally, the report Global Healthcare Nanotechnology (Nanomedicine) Market 2020 describes the Healthcare Nanotechnology (Nanomedicine) industry expansion game plan, the Healthcare Nanotechnology (Nanomedicine) industry knowledge supply, appendix, analysis findings, and the conclusion.

About 360 Market Updates:

360 Market Updates is a credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is to provide a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision-makers in finding the most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Info: -

360 Market Updates

Mr. Ajay More

USA: +1 424 253 0807

UK: +44 203 239 8187

sales@360marketupdates.com

CHECK OUT OUR OTHER RELATED REPORTS:-

Ultracentrifuge Market Size 2020: Industry Size, Share, Future Challenges, Revenue, Demand, Industry Growth and Top Players Analysis to 2025

Global Data Center Construction Market Size 2020 Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2024

Linear Stepper Motors Market 2020 -Key Leaders Analysis, Segmentation, Growth, Future Trends, Gross Margin, Demands, Emerging Technology by Regional Forecast to 2026 - 360 Market Updates

Mill Rolls Market Trends, Size, Share, Growth, Top Manufacturers, Recent Development and Forecast by 2026 | 360 Market Updates

Depyrogenated Sterile Empty Vials Market Size, Share, Growth, Top Manufacturers, Recent Development and Forecast by 2026 | 360 Market Updates

Big Data in Oil and Gas Exploration and Production Market 2020 Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2020-2024 By 360 Market Updates

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Global Healthcare Nanotechnology (Nanomedicine) Market Top Countries Data 2020 Industry Size Analyzed by Business Opportunity, Development, Growth Factors, Applications Analysis and Future Prospects By 360 Market Updates

COMTEX_368577544/2598/2020-07-29T02:36:40

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Read more from the original source:
Global Healthcare Nanotechnology (Nanomedicine) Market Top ...

Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments – PRNewswire

Posted on November 11, 2020 by Prof Baldwin

PALM BEACH, Fla., Nov. 11, 2020 /PRNewswire/ --Academia and industry around the world are working from basic research to advanced technology to alleviate the effects of the COVID19 health crisis. The application of nanoscience and nanotechnology concepts and tools is a good approach within the current global priority. Nanomedicine may provide the fastest-track to the multitude of health issues that are embodied in the global pandemic. Nanotechnology is a common term for nanoscale science, engineering and technology, which offers extraordinary economic and technological benefits. Healthcare is one of the most prominent field of research in nanotechnology. Nanomedicine can be understood as a field of diagnosing, treating and preventing disease using molecular tools and knowledge of the human body. Nanomedicine can address many essential medical problems by using nanomaterials and by obtaining clarity on their interaction with biological systems. Nanomedicine products have various potential applications such as in drug delivery, in vivo imaging, in vitro diagnostics, regenerative medicine, dental, medical devices, and dermal applications. Researchers are turning to nanotechnology to look for answers.Active Biotechs in the markets today include: NanoViricides, Inc. (NYSE: NNVC), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Altimmune, Inc. (NASDAQ: ALT), Eli Lilly and Company's(NYSE: LLY), Pfizer Inc. (NYSE: PFE).

One industry publication (IOPScience) during a report focused on nanotechnology said: "The novel coronavirus pneumonia pandemic was declared as 'public-health emergency of international concern' by the World Health Organization on 30 January 2020. The sudden emergence has triggered alarm for instant management using anti-viral measures and diagnostic tools Taking into consideration the current severity of this disease and the imperative need of SARS-CoV-2 specific treatment and diagnostic tools, nanotechnology-based approaches can provide promising alternatives to conventional ways of disease diagnosis, treatment, and preventing exposure to SARS-CoV-2."

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today reported that it has engaged Calvert Labs, a contract research organization ("CRO"), for performing the Safety Pharmacology studies of its clinical drug candidate for the treatment of COVID-19.

The Company has been diligently working on advancing its drug candidates for the treatment of COVID-19 towards human clinical trials as rapidly as feasible.

The Company intends to perform certain core safety pharmacology studies to ensure safety of the drug candidates at Calvert Labs. The data from these studies will be used for filing an IND application. Prior to that, the Company also intends to file a pre-IND application with the U.S. Food and Drug Administration ("FDA") to obtain guidance.

The recent increase in COVID-19 cases worldwide has led scientists to suggest that this pandemic virus is expected to become a circulating virus. Influenza viruses and common cold viruses are other examples of circulating viruses. However, SARS-CoV-2 is more virulent, and thereby causes substantially greater morbidity and mortality than these other circulating viruses. Therefore, development of an effective drug to treat the disease caused by SARS-CoV-2 is very important.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) the ability of the virus to infect host cells and simultaneously and (ii) the ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies. Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

INOVIO (NASDAQ: INO) a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, this week reported financial results for the quarter ended September 30, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including near-term expectations for its COVID-19 DNA vaccine development program and a clinical program update for its DNA medicines portfolio. The live webcast and a replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, recently announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune's next-generation, single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.

Alberto Santagostino, SVP, Head of Cell and Gene Technologies for Lonza, commented, "We are deeply committed to fighting this global pandemic and deploying our expertise and resources to help vaccine developers like Altimmune meet commercial manufacturing requirements for novel and promising vaccine candidates. Lonza is proud to be well-positioned to support these companies in their mission to serve such critical public health needs."

The U.S. Food and Drug Administration (FDA) recently granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) this week announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

See more here:
Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments - PRNewswire

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer -…

Posted on November 19, 2020 by Prof Baldwin

Regulatory News:

NANOBIOTIX (Euronext: NANO ISIN: FR0011341205 the Company) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the United States Food and Drug Administration (FDA) has provided Safe to Proceed notifications for two additional trials in its ongoing clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). These trials were co-developed with Nanobiotix and MD Anderson is the sponsor and executor.

Significant Unmet Needs and Opportunity in Cancer Immunotherapy

Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. However, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). These barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers.

Combining ICIs with radiation therapy is emerging as a valuable strategy to prime an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues.

NBTXR3 is injected one time, directly into solid tumors. The product candidate is designed to increase the energy deposit from radiation therapy within the target tumor and subsequently increase the tumor-killing effect without increasing toxicity in surrounding healthy tissue. Pre-clinical and clinical data also suggest that NBTXR3 activated by radiation therapy can prime the immune system, creating an anti-tumor immune response that produces both local and systemic effects.

A Phase II Study of NBTXR3 Activated by Radiation and Combined with Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Limited PD-L1 Expression or Refractory to PD-1 Blockade

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objective of the study is to evaluate tumor response of NBTXR3 activated by radiation therapy in combination with pembrolizumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

The population includes patients with inoperable R/M HNSCC of the oropharynx, oral cavity, hypopharynx, larynx or neck. Patients could be anti-PD-1/L1 nave or refractory. Up to 60 patients may be treated, with up to 40 in the first cohort and up to 20 in the second cohort. The first cohort will include anti-PD-1/L1 nave patients with a combined positive score (CPS) between greater than or equal to 1% and less than 20%. The second cohort will include anti-PD-1/L1 refractory patients irrespective of PD-L1 expression.

A Phase II Study of Reirradiation with NBTXR3 in Patients with Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

This MD Anderson trial is an open label, two cohort, non-randomized phase II study. The primary objectives of the study are: (i) to estimate progression-free survival (PFS) and the early clinical benefit in patients treated with NBTXR3 activated by SBRT re-irradiation, with concurrent pembrolizumab; (ii) to assess the safety profile and estimate the early clinical benefit of NBTXR3 activated by a reduced dose of IMRT or IMPT re-irradiation with concurrent pembrolizumab.

The population includes patients with inoperable, locoregional recurrent head and neck squamous cell carcinoma (HNSCC) or second primary HNSCC, previously treated with definitive radiation therapy and without radiographic evidence of metastases. Patients could be anti-PD-1/L1 nave or non-responders. Up to 80 patients may be treated, with up to 60 in the SBRT cohort and up to 20 in the IMRT/IMPT cohort.

***

About NBTXR3

NBTXR3 is a novel, potentially first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The primary mode of action (MoA) of NBTXR3 is designed to generate increased cellular destruction when activated by radiation therapy without increasing damage to healthy tissues. Subsequently, this cellular destruction also triggers an adaptive immune response.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.

About NANOBIOTIX: http://www.nanobiotix.comIncorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005910/en/

Nanobiotix

Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835

contact@nanobiotix.com

Investor Relations DepartmentRicky BhajunSenior Manager, Investor Relations+33 (0)1 79 97 29 99

investors@nanobiotix.com

Media Relations

France Ulysse CommunicationPierre-Louis Germain

+ 33 (0)6 64 79 97 51

plgermain@ulysse-communication.com

See the article here:
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer -...

Healthcare Nanotechnology (Nanomedicine) Market Growth and Demand 2020 Global Industry Segmentation Analysis by Manufacturing Size, Trending Status of…

Posted on July 25, 2020 by Prof Baldwin

The Healthcare Nanotechnology (Nanomedicine) Market report covers the overview of the market and presents the information on business development, market size, and share scenario. The report also emphasizes on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market for the period 2020-2024. The report covers market characteristics for each segmentation across the key regions and country and traces the historic and forecast analysis of the industry. The report covers key vendors their revenue, breakdown by regions, and product demand. Other key details include volume, installed capacity, value chain.

Scope of the Report:

As per the , the healthcare nanotechnology (nanomedicine) market includes products that are nanoformulations of the existing drugs or new drugs or are nanobiomaterials. The market is segmented by its application in the medical field, as drug delivery, biomaterials, active implants, diagnostic imaging, tissue regeneration, and other applications. The market is also segmented by its use in the treatment of diseases, like cardiovascular diseases, oncological diseases, neurological diseases, orthopedic diseases, infectious diseases, and other diseases.<

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

The report provides key statistics on the market status of the Healthcare Nanotechnology (Nanomedicine) Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Healthcare Nanotechnology (Nanomedicine).

Purchase this Report (Price 4250 USD for a single-user license) https://www.industryresearch.co/purchase/14099195

Key Insights of Healthcare Nanotechnology (Nanomedicine) Market:

Healthcare Nanotechnology (Nanomedicine) Market Report Covers Following Points in TOC:

For Detailed TOC Click Here

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Electric Discharge Machine Market Share, Top Manufacturers 2020 Future Growth Rate, Industry Size, Business Strategy, Demand Status by 2026 Research Includes COVID-19 Analysis

Halquinol Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

GRE Pipes Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Copper Cable Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Hemodialysis Concentrates & Powders Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Closed Cell Elastomeric Foam Market 2020 Share, Segment and Growth Technologies by Company Profiles, Future Scope with Regions, Trends Insights, Global Industry Forecast till 2026

See the original post here:
Healthcare Nanotechnology (Nanomedicine) Market Growth and Demand 2020 Global Industry Segmentation Analysis by Manufacturing Size, Trending Status of...

Global Healthcare Nanotechnology (Nanomedicine) Market 2020 Latest Industry Growth Analysis by Upcoming Trends, Emerging Technology by Regions, Supply…

Posted on July 31, 2020 by Prof Baldwin

The Healthcare Nanotechnology (Nanomedicine) Market report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Healthcare Nanotechnology (Nanomedicine) market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Healthcare Nanotechnology (Nanomedicine) market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Healthcare Nanotechnology (Nanomedicine) market that will impact the demand during the forecast period.

Scope of the Report:

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14099195

Market Overview:

Some of the Top Key Players of Healthcare Nanotechnology (Nanomedicine) Market Report Are:

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

North America is Expected to Hold the Largest Share in the Market

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Weight Management Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

Blockchain Technology Market Development Analysis Contributing Top Vendor Landscape 2020 Global Share & Size, Future Plans by Top Key Players and Economic Growth 2025 with COVID-19 Impact

Unmanned Aerial Vehicle (UAV) Market Development Analysis Contributing Top Vendor Landscape 2020 Global Share and Size, Future Plans by Top Key Players and Economic Growth 2026 with COVID-19 Impact

Sensor ICs Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Automotive Structural Sheet Metal Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Vitamin D Therapy Market 2020 Share, Segment and Growth Technologies by Company Profiles, Future Scope with Regions, Trends Insights, Global Industry Forecast till 2026

View post:
Global Healthcare Nanotechnology (Nanomedicine) Market 2020 Latest Industry Growth Analysis by Upcoming Trends, Emerging Technology by Regions, Supply...

Nanobiotix 2019 Q4 and Annual Revenues – BioSpace

Posted on March 1, 2020 by Prof Baldwin

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN : FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.

2019 Revenues

In K

Twelve months Ended

December 31st, 2019

Twelve months Ended

December 31st, 2018

Revenues

105

Of which licenses

Of which services

Other sales

Revenue for Q4 2019

In K

Q4 2019

Q3 2019

Q2 2019

Q1 2019

Revenues

Of which licenses

Of which services

Activity and results

Nanobiotixs revenue for the fourth quarter amounted to approximatively 20k.

Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.

Overall, Nanobiotixs annual revenue in 2019 amounted to approximatively 68k.

The amount of cash and cash equivalent as of December 31st, 2019 amounted to 35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.

In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.

The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.

On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.

2020 Financial agenda

Nanobiotix plans to announce its financial and operating results as follows:

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France and Cambridge, MA in the U.S.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005446/en/

Go here to see the original:
Nanobiotix 2019 Q4 and Annual Revenues - BioSpace

New Comprehensive Report on Oral Contrast Agent Market to Witness an Outstanding Growth during 2020 2028 with Top Players Like Taejoon Pharm (South…

Posted on July 22, 2020 by Prof Baldwin

Latest Research Report: Oral Contrast Agent industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Oral Contrast Agent Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/39407

Oral Contrast Agent Market competition by top manufacturers as follow: GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India),

The risingtechnology in Oral Contrast Agentmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Barium-based Contrast MediaIodinated Contrast MediaGadolinium-based Contrast MediaMicrobubble Contrast Media

Market Segment by Applications, covers:Cardiovascular DisordersCancerGastrointestinal DisordersMusculoskeletal DisordersNeurological DisordersNephrological Disorders

The research report summarizes companies from different industries. This Oral Contrast Agent Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Oral Contrast Agent is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/39407

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Oral-Contrast-Agent-Market-39407

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post:
New Comprehensive Report on Oral Contrast Agent Market to Witness an Outstanding Growth during 2020 2028 with Top Players Like Taejoon Pharm (South...

Global Nanomedicine Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue Analysis – Editorials 360

Posted on December 7, 2019 by Prof Baldwin

Market share of global Nanomedicine industry is dominate by companies like Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).

Access Report Details at: https://www.themarketreports.com/report/global-nanomedicine-market-by-manufacturers-countries-type-and-application-forecast

Market Segment by Regions, regional analysis covers:

Market Segment by Type, covers:

Market Segment by Applications, can be divided into

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1490823

With the help of 15 chapters spread over 100 pages this report describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Nanomedicine, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Nanomedicine sales channel, distributors, traders, dealers, and research findings completes the global Nanomedicine market research report.

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1490823

View original post here:
Global Nanomedicine Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue Analysis - Editorials 360

Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,…

Posted on January 23, 2020 by Prof Baldwin

The Global Nanomedicine Market research report includes various topics like total industry size, key drivers, challenges, growth opportunities, share, growth, demand, outlook etc. it covers key market updates, the impact of regulations and technological updates.

The report addresses the need to stay updated in this competitive industry conditions and this provides and comprehensive data for making strategies and decision so as to stimulate the market growth and profitability.

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points within the industrys value chain.

No. of Pages: 124

Inquire more or share questions if any before the purchase on Nanomedicine Industry report @https://www.orianresearch.com/enquiry-before-buying/627186

Report Covers Market Segment by Manufacturers: Combimatrix Ablynx Abraxis Bioscience Celgene Mallinckrodt Arrowhead Research GE Healthcare Merck

Market Segment by Type, covers: Quantum dots Nanoparticles Nanoshells Nanotubes Nanodevices

Market Segment by Applications, can be divided into: Segmentation encompasses oncology Infectious diseases Cardiology Orthopedics Others

Order Copy of this Report @https://www.orianresearch.com/checkout/627186

There are 15 Chapters to deeply display the global Nanomedicine market.Chapter 1: Describe Nanomedicine Introduction, product scope, market overview, market opportunities, market risk, and market driving force.

About UsOrian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Here is the original post:
Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,...

Nanomedicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry US – News…

Posted on November 11, 2019 by Prof Baldwin

The Global Nanomedicine Market (2019 2026) research offers a basic overview of the industry including definitions, applications, classifications, and market chain structure. Moreover, in the global Nanomedicine Market report, the key product categories of the market are included. The report comparably demonstrates supportive data related to the dominant players in the market, for instance, product offerings, segmentation, revenue, and business synopsis. The global Nanomedicine Market is as well analyzed on the basis of numerous regions. The firstly the report describes the market overview, cost structure, upstream, and technology. The second part describes the global Nanomedicine market by key players, by application and type.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/nanomedicine-market-ric/505553/request-sample

Competitive Analysis

The global Nanomedicine market report wraps scope and product overview to define the key terms and offers comprehensive information about market dynamics to the readers. This is trailed by the regional outlook and segmental analysis. The report also consists of the facts and key values of the global Nanomedicine market in terms of sales and volume, revenue and growth rate.

One of the important factors in the global Nanomedicine market report is competitive analysis. The report covers all the key factors, such as product innovation, market strategies of the key players, market share, revenue generation, latest research and development, and market expert views.

The followingTopmanufacturersare assessed in this report:

AffilogicLTFNBergmannstrostGrupo PraxisBiotechrabbitBraccoMaterials ResearchCentreCarlina technologiesChemConnectionCIC biomaGUNECIBER-BBNContiproCristal TherapeuticsDTIEndomagneticsFraunhofer ICT-IMMTecnaliaTeknikerGIMACIMDEAIstec CNRSwedNanoTechVicomtechVITO NV

Nanomedicine Market Segmentation

For the better grasp insight of the market, this report has provided a detailed analysis of drivers restraints, and trends that dominate the present market scenario and also the future status of the global Nanomedicine market during the projected period of 2018-2026.

Market Analysis by Product Type

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Market Analysis by End-User Application

Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

While classifying these segments, the expert team of analysts has listed the relative contribution of each segment for the growth of the global Nanomedicine market. Detail information of segments is required to recognize the key trends influencing the global market for the Nanomedicine.

Each segment of the market provides a piece of in-depth information on the qualitative and quantitative aspects of the market. While giving a brief idea about the revenue opportunities for all the segments, this report has also provided the value of absolute dollar opportunity for all the segments over the predicted period of 2018 2026.

Regional Analysis

The significant regions covered in the reports of the global Nanomedicine market are North America, Europe, the Asia Pacific, South America, and the Middle East and Africa. The market information not only provides the market data of the five geographies as a whole, but it also provides you qualitative as well we qualitative information on country level bifurcation. Adding to that, economic, technological, cultural and social aspects along with the regulatory barriers are entirely analyzed to understand the thorough market scenario across different geographies.

The key highlight of the Research:

Key Questions Answered:

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email help@researchindustry.us

Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes – Advanced Science News

Posted on December 3, 2019 by Prof Baldwin

Metal nanoclusters, made up of several to one hundred metal atoms (e.g., Au, Ag, Cu, Pt), are a novel class of intermediate between metal atoms and nanoparticles. As their size (<2 nm) borders on the Fermi wavelength of electrons, metal nanoclusters possess strong photoluminescence in comparison with large metal nanoparticles (>2 nm). This, combined with tunable fluorescence emissions, high photostability, good quantum yields and facile synthesis, make them excellent fluorescent labels for biomedical applications.

However, the reduction of metal ions in liquid solution during synthesis usually causes large nanoparticles rather than small metal nanocluster formation because of their tendency to aggregate. In light of this, proteins whose thiol, amino, and carboxyl groups have a strong affinity for metal atoms are typically used to stabilize metal nanoclusters to protect them from aggregationthese proctected clusters are commonly called protein-protected metal nanoclusters.

Protein-protected metal nanoclusters have excellent biocompatibility and have received considerable attention as a luminescent probe in a number of fields such as biosensing, bioimaging, and imaging-guided therapy. However, apart from unique optical properties, protein-protected metal nanoclusters also possess interesting biological properties such as enzyme-like activity similar to that of natural enzymes; until recently, this has been an overlooked quality that is starting to shine in basic research and practical applications.

Nanozymes is a new termed used to refer to nanomaterials with intrinsic enzyme-like activity. Since professor Yan and coworkers first discovered that nanoparticleswhich are traditionally assumed to be inertpossessed intrinsic enzyme-like activity, a substantial amount of work has focused on further developing and harnessing the advantageous properties of nanozymes, which include high catalytic ability, high stability, and low cost. Nowadays, more than 540 kinds of nanomaterials, which possess intrinsic enzymatic activity, have been reported from 350 laboratories in 30 countries and have been used in biological analysis, environmental treatment, as antibacterial agents, cancer therapy, and antioxidation therapy.

In a recent study published in WIREs Nanomedicine and Nanobiotechnology, Professor Xiyun Yan and Kelong Fan explore the newly developing field of biologically active protein-protected metal nanoclusters, namely those that possess peroxidase, oxidase, and catalase activities, and are consequently used for biological analysis and environmental treatment.

An intriguing example of this is bovine serum albumin-protected gold (Au) nanoclusters, which exhibit peroxidase enzymatic activity to catalyze the oxidation of colored organic substrates, which is currently carried out using natural peroxidases. This method showed an advantage over the natural peroxidase-based methods because bovine serum albumin-protected Au nanoclusters exhibited higher robustness and retained enzymatic activity over a wide range of pH and temperatures. In another example, lysozyme-protected platinum (Pt) nanoclusters exhibit oxidase enzymatic activity which has been applied to the oxidative degradation of pollutants, such as methylene blue in lake water.

The proteins themselves not only provide protection and stabilization during synthesis, but can also provide a myriad of other functions to the nanoclusters. Proteins have been shown to enable in vivo applications because of their enhanced biocompatibility. In fact, a protease-responsive sensor for in vivo disease monitoring was designed by utilizing the peroxidase activity of peptide-protected Au nanoclusters and their ultra-small size dependent tumor accumulation and renal clearance properties.

The sensor was developed using peptides which are the substrates/targets of disease related proteases as protective ligands to synthesis the Au nanoclusters nanozymes, which were then conjugated to a carrier. After reaching the site of disease, the sensor was disassembled in response to the dysregulated protease and the liberated Au nanoclusters were filtered through the kidneys and into urine to produce a rapid and sensitive colorimetric readout of diseases state. By employing different enzymatic substrate as protective ligands for Au nanoclusters, this modular approach could enable the rapid detection of a diverse range of diseases with dysregulated protease activities such as cancer, inflammation, and thrombosis.

These findings have extended the horizon of protein-protected metal nanoclusters properties as well as their application in various fields, says Kelong Fan. Furthermore, in the field of nanozymes, protein-protected metal nanoclusters have emerged as an outstanding new addition. Due to their ultra-small size (<2 nm), they usually have higher catalytic activity, more suitable size for in vivo application, better biocompatibility and photoluminescence in comparison with large size nanozymes. We think that ultra-small nanozymes based on protein-protected MNCs are on the verge of attracting great interest across various disciplines and will stimulate research in the fields of nanotechnology and biology.

Despite the advantages and advancedprogress in the development of protein-protected metal nanoclusters asultra-small nanozymes, there are still some challenges that need to be addressedin future work.

First, most researchers still only rely on bovine serum albumin as both the reducing agent and stabilizer. Since we know that protein-protected metal nanoclusters may retain the bioactivity of the protein ligand, it is necessary to explore methods for synthesizing other new protein-protected metal nanoclusters, which will widen the diagnostic and therapeutic applications of protein-protected metal nanoclusters nanozymes.

Second, there are six types of catalytic reactions in nature: oxidoreductases, transferases, hydrolases, isomerases, ligases, and lyases. Thus far, although many protein-protected metal nanoclusters have demonstrated enzyme activities they all are oxidoreductase-like activities such as peroxidase, oxidase, and catalase. Therefore, there is a ample room to develop other types of nanozymes based on protein-protected metal nanoclusters. In this regard, more understanding of the structures and catalytic mechanisms of protein-protected metal nanoclusters is required in addition to the deeper understanding on natural enzymes themselves.

Third, a considerable number of reports have suggested that ultra-small nanozymes based on protein-protected metal nanoclusters are promising tools for biological analysis. However, little is known about the therapeutic function of these ultra-small clusters in vivo despite their advantages of suitable size and good biocompatibility. It is well known that peroxidase, oxidase, and catalase are main enzymes in biological systems involved in the maintenance of redox homeostasis. Thus, more attention should be paid to the usage of these ultra-small nanozymes based on protein-protected metal nanoclusters as bio-catalysts in various human diseases involved in redox dysregulation such as cancer, inflammation, cardiovascular diseases. It is also possible to employ the products of redox nanozymes to treat other diseases, for example, use the toxic hydroxyl radicals produced by peroxidase nanozymes to treat bacterial infection.

Overall, there is still much room for future research and application of ultra-small nanozymes based on protein-protected metal nanoclusters. It is expected that the enzyme-like activity of protein-protected metal nanoclusters will certainly attract broader interests across various disciplines and stimulate research in the fields of nanotechnology and biology, making these emerging ultra-small nanozymes become novel multifunctional nanomaterials for a number of biomedical applications.

Kindly contributed by the authors.

View original post here:
Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes - Advanced Science News

Converging on cancer seminar series engineering and physical science to advance cancer research (Chemistry and Bioengineering) – Imperial College…

Posted on October 31, 2021 by Prof Baldwin

In this series of webinars brought to you by the Cancer Research UK Convergence Science Centre at Imperial College London and The Institute of Cancer Research, London, researchers across the two organisations will discuss key challenges facing cancer research and opportunities for new convergence science approaches to address these. Join us to consider how novel approaches and technologies could shed light on unresolved problems in cancer biology, to innovate new ways to address challenges in cancer and bring pioneering treatments to cancer patients faster.

Hosted by the Convergence Science Centres Scientific Director Professor Axel Behrens, the series aims to support the Centres mission to facilitate collaboration between traditionally separate and distinct disciplines.

Please join us onThursday 4th November, from 15.00-16.00, for two talks from:

Dr Nazila Kamaly Department of Chemistry, Imperial College London

Nanomedicines and their role in modern cancer therapy

Nanoparticle enabled drug delivery and therapy is revolutionising the field of medicine, as we have witnessed recently with the solid lipid nanoparticle based Covid-19 mRNA vaccines. Since the last two decades, the application of nanotechnology in oncology has aimed to provide more effective and safer cancer treatment, with commonly used nanotherapies such as Doxil now on the market as nanosimilars. Considerable technological success has been achieved in this field though we have not seen a new paradigm shift in cancer therapy with nanomedicines. This is in part due to challenges stemming from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano-bio interactions and complex chemistries, scale-up, manufacturing and controls required for clinical translation and commercialisation, which the field is actively addressing and will be discussed in this talk.

Dr. Nazila Kamaly is a lecturer in the Department of Chemistry and nanomedicine expert. She uses bioinspired approaches to develop targeted multi-functional polymeric nanomedicines capable of changing their surface or core properties in response to local or up-regulated disease markers for stimuli-responsive and spatiotemporally controlled precise drug delivery. Her lab also develops biomimetic and biomicrofluidic models to better screen and understand nano-bio interactions at the cellular level.

Dr Nuria Oliva-Jorge Department of Bioengineering, Imperial College London

Tumour-selective cancer nanotherapies

In this talk, Dr. Oliva-Jorge will describe novel approaches being developed in her group to elicit tumour-selectivity of cancer therapeutics using nanotechnology. It is not uncommon for potent anti-cancer drugs to have dose-limiting toxicity, due to their unintended effects on healthy cells. Using rational nanoparticle design and engineering, we can enable selective nanoparticle uptake and/or drug release in cancer cells only, minimising this way the side effects on healthy cells.

Dr. Nuria Oliva-Jorge is currently an Imperial College Research Fellow in the Department of Bioengineering. An organic chemist by training, Nuria received her PhD in Medical Engineering and Medical Physics from MIT in 2016. Her thesis focused on biomaterials combined with nanotechnology for the local treatment of breast cancer. In 2018, Nuria joined the Almquist Lab at Imperial College London as a postdoctoral fellow to work on nanotechnologies for wound healing and tissue regeneration. Her independent group works at the intersection of biomaterials, biology and medicine to develop novel, smart medical technologies to tackle complex human diseases.

To receive information about how to access this event please emailicr-imperial-convergence.centre@imperial.ac.uk

Please note: This webinar is exclusively available only to colleagues across the Institute of Cancer Research, Imperial College London, the Royal Marsden Hospital and Imperial College Healthcare.

Go here to see the original:
Converging on cancer seminar series engineering and physical science to advance cancer research (Chemistry and Bioengineering) - Imperial College...

Nanomedicine in Malaria Treatment – Video

Posted on March 5, 2015 by Prof Baldwin

Nanomedicine in Malaria Treatment
Speaker: Paula Melariri CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

See more here:
Nanomedicine in Malaria Treatment - Video

NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range – Business Wire

Posted on December 13, 2020 by Prof Baldwin

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the filing of an amended registration on form F-1 in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares (ADSs), each representing the right to receive one ordinary share, in the United States (the U.S. Offering) and a concurrent offering of ordinary shares in certain jurisdictions outside the United States to certain investors (the European Offering and together with the U.S. Offering, the Global Offering). The offering price per ADS is expected to be between $13.50 and $14.50, or between 11.15 and 11.97 per ordinary share (assuming an exchange rate of 1.00 = $1.2109, the exchange rate published by the European Central Bank on December 9, 2020).

Assuming an offering price of $14.00 per ADS in the U.S. Offering and 11.56 per ordinary share in the European Offering, which are the midpoints of the respective price ranges, the Company expects to receive net proceeds of approximately $79.6 million (65.8 million) from the Global Offering. The Company intends to grant the underwriters a 30-day option to purchase, at the same price, additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering. If such option is exercised in full, the expected net proceeds to the Company will increase to approximately $92.3 million (76.2 million).

All securities to be sold in the Global Offering will be offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Select Market under the ticker symbol NBTX. The Companys ordinary shares are listed on the regulated market of Euronext Paris under the ticker symbol NANO.

The Company plans to use the net proceeds of the Global Offering to advance the overall development of NBTXR3, prioritizing the treatment of locally advanced head and neck cancers, including approximately $58.1 million to advance its clinical trial of NBTXR3 in the United States and Europe for the treatment of locally advanced head and neck cancers through an interim analysis of efficacy data, and approximately $20.6 million to advance the development of its other clinical and pre-clinical programs. The Company expects to use the remainder of the net proceeds, if any, from the Global Offering for working capital funding and other general corporate purposes.

The Company expects that the net proceeds from the Global Offering, together with its cash and cash equivalents of 42.4 million as of September 30, 2020, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2022.

Jefferies LLC is acting as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are acting as joint book-running managers for the U.S. Offering. Jefferies International Limited and Gilbert Dupont are acting as managers for the European Offering.

The final offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and ordinary shares to be sold in the Global Offering, will be determined by the Companys executive board following a bookbuilding process commencing immediately. The offering price per ADS and per ordinary share will be at least equal to the volume weighted average price of the Companys ordinary shares on the regulated market of Euronext in Paris over the last three trading days preceding the start of the offering (i.e., December 7, 8 and 9, 2020), subject to a maximum discount of 10%.

On an indicative basis, the completion of the Global Offering would result in a dilution of approximately 25% of the Company's outstanding share capital on a non-diluted basis (excluding the exercise by the underwriters of the option to purchase additional ordinary shares) and approximately 28% of the Companys outstanding share capital on a non-diluted basis (in the event that the underwriters exercise in full their option to purchase additional ordinary shares (including in the form of ADSs)).

The ADSs and/or ordinary shares will be issued through a capital increase without shareholders preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1 of the French Monetary and Financial Code (Code montaire et financier) and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the 2nd and 7th resolutions of the Company's extraordinary general shareholders' meeting held on November 30, 2020. The European Offering will be open only to qualified investors as such term is defined in article 2(e) of the regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017.

The Company plans to announce the result of the Global Offering as soon as practicable after pricing thereof in a subsequent press release.

The existing liquidity contract between the Company and Gilbert Dupont is suspended until the end of the stabilization period.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement on Form F-1 relating to the securities referred to herein has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement can be accessed by the public on the website of the SEC.

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). Its headquarters are in Paris, France. Nanobiotix has a subsidiary, Curadigm, located in France and the United States, as well as a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning the Global Offering as well as Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the AMF under number R.20-010 on May 12, 2020 and in its amendment filed with the AMF under number D.0339-A01 on November 20, 2020 (copies of which are available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs of Nanobiotix in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

A French listing prospectus comprising (i) the 2019 universal registration document filed with the AMF under number R.20-010 on May 12, 2020, as completed by a first amendment to such universal registration document filed with the AMF under number D.0339-A01 on November 20, 2020 and a second amendment to such universal registration document, which will be filed with the AMF on December [11], 2020, and (ii) a Securities Note (Note dopration), including a summary of the prospectus, will be submitted to the approval by the AMF and will be published on the AMFs website at http://www.amf-france.org. Following the filing of the second amendment to the universal registration document with the AMF, copies of Companys 2019 universal registration document, as amended, will be available free of charge at the Companys head office located at 60 rue de Wattignies, 75012 Paris.

European Economic Area

In relation to each Member State of the European Economic Area (each, a "Member State") no offer to the public of ordinary shares and ADSs may be made in that Member State other than:

For the purposes of this provision, the expression an "offer to the public" in relation to any ordinary shares and ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares and ADSs to be offered so as to enable an investor to decide to purchase any ordinary shares and ADSs, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 (as amended).

France

The ADSs and the ordinary shares have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to the ADSs and the ordinary shares may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1 of the French Code montaire et financier).

The ordinary shares in the form of ADSs may only be offered or sold in France pursuant to article L. 411-2 1 of the French Code montaire et financier to qualified investors (as such term is defined in Article 2(e) of Regulation (EU) n 2017/1129 dated 14 June 2017, as amended) acting for their own account, and in accordance with articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4, D.744-1 and D. 754-1 and D. 764-1 of the French Code montaire et financier.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

MIFID II product governance / Retail investors, professional investors and ECPs only target market Solely for the purposes of each manufacturers product approval process, the target market assessment in respect of the new shares has led to the conclusion that: (i) the target market for the new shares is retail investors, eligible counterparties and professional clients, each as defined in MiFID II; and (ii) all channels for distribution of the new shares to retail investors, eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the new shares (a distributor) should take into consideration the manufacturers target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the new shares (by either adopting or refining the manufacturers target market assessment) and determining appropriate distribution channels. For the avoidance of doubt, even if the target market includes retail investors, the manufacturers have decided that the new shares will be offered, as part of the initial offering, only to eligible counterparties and professional clients.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Follow this link:
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range - Business Wire

New Report On, Healthcare Nanotechnology (Nanomedicine) Market 2020 Global Impressive CAGR of 0%, Top Countries Industry Trends, Share, Size, Demand,…

Posted on July 21, 2020 by Prof Baldwin

Worldwide Healthcare Nanotechnology (Nanomedicine) Market 2020 Provides Market Share, CAGR, Production, Consumption, Revenue, Gross Margin, Price And Market Manipulating components of the Healthcare Nanotechnology (Nanomedicine) business in worldwide areas. This report is extensive numerical investigations of the Healthcare Nanotechnology (Nanomedicine) business and gives information to making procedures to expand the market development and achievement. The Report additionally gauges the market size, Price, Revenue, Gross Margin and Market Share, cost structure and development rate for dynamic.

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, limitations, opportunities, and threats. This information can help shareholders to make suitable decisions before investing.

Brief Description about Healthcare Nanotechnology (Nanomedicine) market:

Rising applications in Oncology

Huge costs of the medical devices

US Healthcare Nanotechnology Market

The US-based pharmaceutical companies believe that nanomedicines is the next big thing, as it has been opening up newer and has more accurate options for the target drug delivery, and resulting in very few side effects. The Swiss Groups Kadcyla received the approval of the United States in February 2017. The product treats breast cancer with very less side-effects. In addition with the booming R&D, United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in healthcare. Owing to the large geriatric population, increasing need for diagnostics, growing need of augmented cancer therapies, government initiatives, and increasing awareness of nanomedicines, the US healthcare nanotechnology sector will witness substantial growth during the forecast period.

The key players in the market are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS Inc., JOHNSON & JOHNSON, MALLINCKRODT Plc, MERCK & COMPANY, Inc., NANOSPHERE, Inc., PFIZER, and CELGENE CORPORATION.

Request a Sample Copy of the Healthcare Nanotechnology (Nanomedicine) Market Report 2020

Research objectives:

Major Countries play vital role in Healthcare Nanotechnology (Nanomedicine) market:

Inquire or share your questions if any before the purchasing this report @ https://www.360researchreports.com/enquiry/pre-order-enquiry/13100546

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Detailed TOC of Global Healthcare Nanotechnology (Nanomedicine) Market Segmented by Platform, Purpose, and Geography Growth, Trends

1.Introduction

1.1 Study Deliverables

1.2 General Study Assumptions

2.Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3.Executive Summary

4.Market Overview and Trends

4.1 Introduction

4.2 Market Trends

4.3 Porters Five Force Framework

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Consumers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry within the Industry

5.Market Dynamics

5.1 Drivers

5.2 Restraints

Continued

Purchase this report (Price 4250 USD for a single-user license) @ https://www.360researchreports.com/purchase/13100546

About 360 Research Reports:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact:

360 Research Reports

Mr. Ajay More

USA :+1 424 253 0807

UK :+44 203 239 8187

[emailprotected]

related reports:

Light Soda Ash Market 2020 Top Countries Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential from 2020-2026

Solar Cell Metal Paste Market 2020 to Showing Impressive Growth by 2024, Top Countries Industry Trends, Share, Size, Top Key Players Analysis and Forecast Research

Polishing Powder Market 2020 Top Countries Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential from 2020-2024

Link:
New Report On, Healthcare Nanotechnology (Nanomedicine) Market 2020 Global Impressive CAGR of 0%, Top Countries Industry Trends, Share, Size, Demand,...

Nanomedicine Market 2020 Expected to Reach at Highest Revenue, Prosperous Growth, Recent Trends and Demand by Top Key Vendors like GE Healthcare,…

Posted on September 3, 2020 by Prof Baldwin

Nanomedicine MarketReport offers detailed insight, industry knowledge, market forecasts, and analytics. This market research studies aim to predict market size and future growth potential across sectors such as suppliers, industries and regions. This research report also combines industry-wide statistically relevant quantitative data and relevant and insightful qualitative analysis. Report also analyzes noteworthy trends, emerging value of CAGR and present as well as future development.

The report focuses on market contributions and provides a brief introduction, a business overview, revenue distribution, and product doses. This research report comprises exclusive and important factors that could have a noteworthy impact on the development of the global market during the forecast period of 2020-2027.

Ask for Sample of Report at https://www.healthcareintelligencemarkets.com/request_sample.php?id=26334

Top Key Players:

Regional Analysis:

As the demand for new innovative solutions increases and more startups arise in the space which leads to growth and excessive demand for the Nanomedicine Market in 2020 to 2027.This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Inquire For a Discount on Report at https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=26334

Theglobal Nanomedicine Market Reportanalyzes opportunities in the stakeholder market by identifying the high-growth sectors of the market. Identify key customers in the marketplace and comprehensively analyze key competencies such as new product launches. Partnerships, agreements and cooperation.

Major Points Covered in Table of Contents:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Complete Report is available at https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=26334

About Us:

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Marvella Lit

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: [emailprotected]

Web: http://www.healthcareintelligencemarkets.com

Phone: +44-753-712-1342

Link:
Nanomedicine Market 2020 Expected to Reach at Highest Revenue, Prosperous Growth, Recent Trends and Demand by Top Key Vendors like GE Healthcare,...

Top Providers Of The Global Nanomedicine Market Demand with Leading Key Players 2020 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc -…

Posted on December 15, 2019 by Prof Baldwin

New York City, NY:December 15, 2019 Published via (Wired Release) Outline: The study on the GlobalNanomedicineMarket Research Report 2019 proposes complete data on the Factors, Report example, SWOT investigation, situation, analysis, size, main players, of the business, and most useful guides in the market are covered in the report. In addition to this, the report opponent numbers, tables, and charts that offer a distinct viewpoint of the Nanomedicine market. The top Players/Vendors Comp such as GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Pfizer Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A, Prudential of the global Nanomedicine market are further covered in the report.

Scope of The Report:

The newest data has been revealed in the examination of the wealth figures, stock details, and acquisitions of the major firms. The report on the global Nanomedicine market furthermore offers a sequential factsheet relating to the strategical mergers, acquirements, joint venture activities, and partnerships widespread in the Nanomedicine market. Astonishing recommendations by senior experts on strategically sharing in innovative output may help best in class competitors and in addition, trustworthy organizations for an improved invasion in the creating portions of the Global Nanomedicine Market players might accomplish a clear perception of the main rivals in the Nanomedicine market in addition to their future forecasts.

Request Research Report Specimen (Use Corporate Email ID For Higher Priority):https://market.us/report/nanomedicine-marketrequest-sample

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

In addition to this, the report also covers the analysis of the revenue for the global Nanomedicine market in extension to claiming a forecast for the same in the estimated timeframe. The essential business plans endorsed by the important individuals from the Nanomedicine market have likewise been coordinated in the report. Fundamental weaknesses and strengths, in extension to declaring the risks encountered by the main contenders in the Nanomedicine market, have been a fraction of this research study.

The Worldwide Nanomedicine Market Is an Enlarging Domain for The Top Market Player:

GE HealthcareJohnson & JohnsonMallinckrodt plcMerck & Co. Inc.Nanosphere Inc.Pfizer Inc.Pfizer Inc.Smith & Nephew PLCStryker CorpTeva Pharmaceutical Industries Ltd.UCB (Union chimique belge) S.A

Industry Analysis By Type:

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Industry Analysis By Applications:

Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

Here Are the Questions We Answer

3. Global Nanomedicine Report mainly covers the following:

1- Nanomedicine Industry Overview

2- Nanomedicine Technical Data and Manufacturing Plants Analysis

3- Region and Country Nanomedicine Market Analysis

4- Production by Regions by Technology by Nanomedicine Applications

5- Productions Supply Sales Demand Market Status and Nanomedicine Market Forecast

6- Nanomedicine Manufacturing Cost Structure and Process

7- Key success factors and Nanomedicine Market Share Overview

8- Nanomedicine Research Methodology

The article also segments the global Nanomedicine market based on product mode and segmentation Type I, Type II. The study includes a profound summary of the key sectors and the segments Personal, Business of the Nanomedicine market. Both instantly and gradually growing sectors of the market have been analyzed via this study. Prediction, opportunity, the share of the market, and volume of each segment and sub-segment is available in the study. The key up-and-coming possibilities associated with the most quickly growing segments of the market are also a part of the report.

Global market volume, supply, sale, consumption, demand, import, export, macroeconomic analysis, sample, and purpose segment report by region, including:

Asia-Pacific Market: China, Southeast Asia, India, Japan, Korea, Western Asia

The Middle East & Africa Market: GCC, North Africa, South Africa

North America Market: United States, Canada, Mexico

Europe Market: Germany, Netherlands, UK, France, Russia, Spain, Italy, Turkey, Switzerland

South America Market: Brazil, Argentina, Columbia, Chile, Peru

More About Customizing Research Report Inquire Here @ (Use Corporate email ID to Get Higher Priority): https://market.us/report/nanomedicine-market#inquiry

Table Of Contain in Report 14 Segment which Clarifies Global Nanomedicine Market Quickly are:

Segment 1. Industry Synopsis of Global Nanomedicine Market.

Segment 2. Nanomedicine Market Size by Type and Application.

Segment 3. Nanomedicine Market Organization Producers analysis and Profiles.

Segment 4. Global Nanomedicine Market 2019 Analysis by key traders.

Segment 5. Segmentelopment Status and Outlook of Nanomedicine Market in the United States.

Segment 6. Europe Nanomedicine Industry Report Segmentelopment Status and Outlook.

Segment 7. Japan Nanomedicine Industry Report Segmentelopment Status and Outlook.

Segment 8. China Nanomedicine Market Report Segmentelopment Status and Outlook.

Segment 9. India Nanomedicine Market Segmentelopment Status and Outlook.

Segment 10. Southeast Asia Nanomedicine Market Improvement Status and Outlook.

Segment 11. Market Figure by Regions, Purposes, and Sorts (2019-2029).

Segment 12. Industry Dynamics.

Segment 13. Research Verdicts and Conclusions.

Segment 14. Appendix.

GET DETAILED ANALYZED RESEARCH REPORT HERE @ https://market.us/purchase-report/?report_id=https://market.us/purchase-report/?report_id=36341

Key Deliverables of Nanomedicine Report Are As Follows:

1. Market overview, definition, scope, size estimation, and Global Nanomedicine Industry maturity analysis.

2. Cost structures, past Nanomedicine Industry performance, market concentration and growth rate from 2012-2029 are analyzed.

3. Nanomedicine Market division by Type, Application and Research regions will lead to clear market understanding.

4. Market value and growth rate across different regions, Global Nanomedicine Market dynamics are explained.

5. The limitations, opportunities and industry plans & policies are elaborated.

6. The production, market share, and consumption from 2012-2018/19 for each Nanomedicine product type, application, and region are specified.

7. Nanomedicine Market production, consumption, the import-export scenario is portrayed.

8. The Nanomedicine industry status and regional SWOT analysis are conducted.

9. Nanomedicine Industry forecast view is presented for type, regions, application for estimation of the future market scope and investment feasibility.

Mr. Benni Johnson

Market.us (Powered By Prudour Pvt. Ltd.)

Email:inquiry@market.us

Address:

420 Lexington Avenue,

Suite 300 New York City,

NY 10170, United States

Tel: +1 718 618 4351

Website:https://market.us

Browse More Report Over Here:Industrial Floor Scrubbers Market (2020-2029) Trends and Top Key Companies Profile | Tennant Company, Factory Cat and Nilfisk-Advance

See the rest here:
Top Providers Of The Global Nanomedicine Market Demand with Leading Key Players 2020 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc -...

Nanomedicine: Market by Recent Trends, Development and Growth Forecast by Regions and Applications 20202025 – Instant Tech News

Posted on February 25, 2020 by Prof Baldwin

Nanomedicine Market Research Report 2020 This Report Is Comprised with Market Data Derived from Primary as Well As Secondary Research Techniques. The Points Covered in The Report Are Primarily Factors Which Are Considered to Be Market Driving Forces. The Report Aims to Deliver Premium Insights, Quality Data Figures and Information in Relevance with Aspects Such as Market Scope, Market Size, Market Share, Market Segments Including Types of Products and Services, Application Areas, Geographies As Well. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Nanomedicine Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Nanomedicine Market Report Incorporates Valuable Differentiating Data Regarding Each of The Market Segments. These Segments Are Studied Further on Various Fronts Including Past Performance, Market Size Contributions, Market Share, Expected Rate of Growth, And More.

The Major Players in the Nanomedicine Market are Profiled in detail in View of Qualities and Share of The Overall Industry.GE HealthcareJohnson & JohnsonMallinckrodt plcMerck & Co. Inc.Nanosphere Inc.Pfizer Inc.Sigma-Tau Pharmaceuticals Inc.Smith & Nephew PLCStryker CorpTeva Pharmaceutical Industries Ltd.UCB (Union chimique belge) S.AKey Businesses Segmentation of Nanomedicine Market

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

In Conclusion, Nanomedicine Market Report Presents the Descriptive Analysis of the Parent Market Based On Elite Players, Present, Past and Futuristic Data Which Will Serve as A Profitable Guide for All the Nanomedicine Market Competitors.

Purchase FULL Report Now! https://www.qurateresearch.com/report/buy/HnM/global-nanomedicine-market/QBI-99S-HnM-655650

Major Players: The report provides company profiling for a decent number of leading players of the global Nanomedicine market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Industry Overview: The first section of the research study touches on an overview of the global Nanomedicine market, market status and outlook, and product scope. Additionally, it provides highlights of key segments of the global Nanomedicine market, i.e. regional, type, and application segments.

Nanomedicine Market Dynamics: The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Regional Market Analysis: It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Global Nanomedicine Market Forecast: Readers are provided with production and revenue forecasts for the global Nanomedicine market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Nanomedicine market by type, and consumption forecast for the global Nanomedicine market by application.

Nanomedicine Market Competition: In this section, the report provides information on competitive situation and trends including merger and acquisition and expansion, market shares of top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Qurate Business Intelligence delivers unique Market research solutions to its customers and help them to get equipped with refined information and Market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Read the original:
Nanomedicine: Market by Recent Trends, Development and Growth Forecast by Regions and Applications 20202025 - Instant Tech News

What is Nanobots & Its Biggest Contribution in The Medical Industry – Robots.net

Posted on October 30, 2019 by Prof Baldwin

Afraid of nanobots rising up and taking over the world? Dont be, that only happens in movies. In the real world, there are types of robots that save the human race, nanorobots to be exact. Experts and professionals are continuously doing extensive research and advanced development in nanotechnology. Research in finding the best uses of nanorobots and nanomachines into the medical industry.

In the field of medicine, theres only a tiny room for error. To be more precise, everything has to be perfect. Of course, professional doctors are highly skilled and knowledgeable to do various surgeries and other treatments to patients. But there are some procedures that require extreme precision that even world-class doctors arent capable of doing.

Imagine a doctor pinpointing cancer cells, or a doctor eliminating the defected parts in someones DNA structure. Those are tasks that are almost impossible to do. But lucky for us, nanorobots and nanomachines exist in our world today. What it does is a guarantee to provide patients with the treatment they need. Hence, giving them a chance to live their lives better and longer.

In this article, well take a deeper look and have a further understanding of what nanobots truly are. We analyze thoroughly from its components, types, to their uses in the medical industry.

Nanorobotics falls under the field of nanotechnology. They deal with the design and development of devices at an atomic, molecular or cellular level. These hypothetical nanorobots are superbly tiny, ranging from 0.1-10 micrometers, capable of traveling inside the human blood. In general, almost all nanorobots have specialized sensors that are able to target molecules. Therefore, it can be programmed to determine and treat targeted diseases.

A nanorobot, also known as nanobot, nanomachines or nanomites, can be made out of different mechanical components. It can be gears or motors using a variety of elements like hydrogen, sulfur, oxygen, nitrogen, silicon and such. On the other hand, the exterior of a nanobot can be created using a diamondoid element due to its dormant characteristics, high thermal conductivity, and durability. They feature extremely smooth surfaces, lessening the possibilities of triggering the bodys immune system.

While an excellent property that nanorobots have is the ability to correlate to each other. Hence, developing a structure with decentralization. Another point is nanobots can do a self-replication process. In which they will create duplicates of themselves and replacing all the non-working units at the same time.

If youre wondering if its possible to communicate with nanorobots, the answer is, yes. All it needs is by encoding messages to acoustic signals at a wave frequency ranging from 1-100 MHz. When the task is completed, these nanorobots can be retrieved through the usual human excretory channels or active scavenger systems can be used.

In constructing nanorobots, there are two main approaches. They are the Positional assembly and the Self-assembly.

In the self-assembly, the nanomachines robotic arm thats used to pick and assemble the molecules are controlled manually by an operator while on the positional assembly, billion of molecules are put together and the nanobots can automatically assemble them into their natural configuration.

Also, nanobots are provided with swarm intelligence for decentralization activity, a technique that was inspired by the behaviors of social animals like ants, bees, etc that can work collaboratively naturally. But in order for the nanobots to function perfectly, they must have these specific components and substructures:

The section where the nanobot holds and releases a small dose of drug/medicine.

The nanorobot may include a miniature camera. The operator can steer the nanorobot when navigating through the body manually

The electrode mounted on the nanorobot could form the battery using the electrolytes in the blood.

These lasers could burn the harmful material like arterial plaque, blood clots or cancer cells.

Use when the nanorobots target and destroy kidney stones.

The nanorobot will need a means of propulsion to get into the body as they travel against the flow of blood in the body.

According to Robert A. Freitas Jr., who has pioneered the study and communication of the benefits to be obtained from advanced nanorobotics and biotechnology, classified nanorobots into three types; Respirocytes, Microbivores, and Clottocytes. He is also responsible for the term Nanomedicine that is commonly used in the field of science today. Lets check out how these three nanobots differ from one another.

First up on our list is the Respirocytes and no, its not the Death Star from Star Wars. Respirocytes are the nanorobots that intend to act as artificial mechanical red blood cells. Its characteristics are the following. First, they are in a spherical blood-borne shape that has 1 micrometer in diameter. Second, it composes of a diamondoid 1000 atm pressure container, the exterior casing. Third, it has reversible molecule-selective pumps.

Respirocytes transport oxygen and carbon dioxide molecules throughout the body. Finally, the respirocyte is a construction of 18 billion atoms. All are accurately arranged in diamondoid pressure tanks. These tanks are capable of storing up to 3 billion oxygen and carbon dioxide molecules. Compared to natural red blood cells, the respirocyte would deliver 236 times more oxygen to the body tissues.

Gas concentration sensors and an onboard nanocomputer can control the respirocyte. Moreover, it manages the carbonic acidity. The stored gases will discharge from the tank in a controlled behavior into the molecular pumps. The respirocytes exchange gases via molecular rotors that have special tips for a particular type of molecule.

Next on our list is the Microbivores. Unlike the Respirocytes, it is an artificial white blood cell that is also known as Nanorobotic Phagocytes.

Microbivores are the nanorobot. It functions as artificial white blood cells and also known as nanorobotic phagocytes. However, this particular nanobot is a spheroid device that consists of a diamond and sapphire. The Microbivers measures 3.4 micrometers in diameter along its major axis and 2.0 micrometers diameter along the minor axis. There are 610 billion of arranged structural atoms are inside the nanobot.

What it does is it traps in the pathogens existing in the bloodstream then breaks down into smaller molecules. While the Microbivores main purpose is to absorb and digest the pathogens in the bloodstream by using the process of phagocytosis. There are four fundamental components of microbivore:

For only 30 seconds, an entire cycle of microbivores phagocytosis will complete. There are no possibilities of septic shock since it has internalized bacterial elements. Also, it digested into non-antigenic biomolecules. The microbivore is 1000 times quicker than antibiotic aided white blood cells. The pathogen also stands no chance of multiple drug resistance.

Taking the third and final spot on our list is the Clottocytes. These nanorobots described as artificial mechanical platelet, designed for Hemostasis. Whats Hemostasis, you say? Let us explain, Hemostasis is the process of blood clotting when theres damage to the endothelium cells of blood vessels by platelets. These platelets will activate by the collision of exposed collagen from damaged blood vessels to the platelets. It will take around 2-5 minutes for the whole process of natural blood clotting.

Clottocytes, on the other hand, can complete the whole process in 1 second approximately. This nanorobot in spherical form is powered by serum-exyglucose. It is about 2 micrometers in diameter and it contains a fiber mesh thats neatly folded inside. When released, the fiber mesh would be biodegradable, a film-like layer of the mesh would disappear in contact with the plasma to reveal the sticky mesh. When compared to the natural hemostatic system, Clottocytes are 100 times if not, 1000 times faster than natural healing.

Nanomites are specifically designed for drug transport called Pharmacytes. The dosage of the drug will load into the payload of the Pharmacyte. And they can precisely transport and target the drug to specific cellular points.

By using nanobots, the patients vitals can be continuously monitored. However, it will lead to a quantum leap in diagnostics.

Dentifrobots are nanorobots that intend for dental treatment. These types of nanomachines can induce oral analgesia, desensitize teeth, manipulate the tissues. Besides, it also uses to realign and straighten irregular sets of teeth.

Nanobot is a program to be self-sufficient onsite surgeons inside the body. Plus, they can do multiple functions. These functions include detecting pathology, diagnosing, correcting lesions. Function coordinated By nano-manipulation by an on-board computer.

Nanorobots are made with a mixture of a polymer. Its transferrin is capable of detecting tumor cells. They feature embedded chemical biosensors, primarily used for detecting tumors

Nanobots carry out glucose molecules into the bloodstream. In order to maintain human metabolism. They use a Chemosensor in which they can modulate the hSGLT3 protein glucose-sensor activity.

Due to the fact that nanorobots can provide better access to the required area, thus it performs micro-surgeries. Moreover, it has extreme precision, they can perform certain surgeries that doctors are not capable of doing.

By medical nanomites, it can treat genetic diseases. Besides, this is by analyzing the molecular composition of DNA and proteins found in the cell. The best part, by using Chromallocytes it can perform Chromosome replacement therapy too.

If nanorobots are really the future of medicine, we are all ready for it. Their precise and efficient performance is definitely something we can rely on. The successful development of Nanobots can unveil new approaches to medical treatment. Hence, resulting in revolutionizing traditional medical treatment that is faster, concise & error-free treatment.

With the constant development and innovation of nanotechnology and nanomedicine, inevitably, more and more of these micrometer nanomachines be developed. Hence, treating more diseases and doing more surgeries, saving more patients in the years to come.

Follow this link:
What is Nanobots & Its Biggest Contribution in The Medical Industry - Robots.net

Futurist Transhuman News Blog

Category Archives: Nanomedicine

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes – GlobeNewswire

Global Healthcare Nanotechnology (Nanomedicine) Market Top …

Nanotechnology Based Approaches For Combating COVID-19 Could Fast-Track New Detection Modalities And Treatments – PRNewswire

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer -…

Healthcare Nanotechnology (Nanomedicine) Market Growth and Demand 2020 Global Industry Segmentation Analysis by Manufacturing Size, Trending Status of…

Global Healthcare Nanotechnology (Nanomedicine) Market 2020 Latest Industry Growth Analysis by Upcoming Trends, Emerging Technology by Regions, Supply…

Nanobiotix 2019 Q4 and Annual Revenues – BioSpace

New Comprehensive Report on Oral Contrast Agent Market to Witness an Outstanding Growth during 2020 2028 with Top Players Like Taejoon Pharm (South…

Global Nanomedicine Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue Analysis – Editorials 360

Nanomedicine Market: 2020 Global Industry Growth Prospects and Insights on Future Scenario | Company Profiles Combimatrix, Ablynx, Abraxis Bioscience,…

Nanomedicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry US – News…

Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes – Advanced Science News

Converging on cancer seminar series engineering and physical science to advance cancer research (Chemistry and Bioengineering) – Imperial College…

Nanomedicine in Malaria Treatment – Video

NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range – Business Wire

New Report On, Healthcare Nanotechnology (Nanomedicine) Market 2020 Global Impressive CAGR of 0%, Top Countries Industry Trends, Share, Size, Demand,…

Nanomedicine Market 2020 Expected to Reach at Highest Revenue, Prosperous Growth, Recent Trends and Demand by Top Key Vendors like GE Healthcare,…

Top Providers Of The Global Nanomedicine Market Demand with Leading Key Players 2020 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc -…

Nanomedicine: Market by Recent Trends, Development and Growth Forecast by Regions and Applications 20202025 – Instant Tech News

What is Nanobots & Its Biggest Contribution in The Medical Industry – Robots.net